|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang JY, Yoshihara K, Tanaka K, Hatae M,
Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research
Network, ; Takano M, Ushijima K, Tanyi JL, et al: Predicting time
to ovarian carcinoma recurrence using protein markers. J Clin
Invest. 123:3740–3750. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holschneider CH and Berek JS: Ovarian
cancer: Epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosenberg L, Palmer JR, Zauber AG,
Warshauer ME, Lewis JL Jr, Strom BL, Harlap S and Shapiro S: A
case-control study of oral contraceptive use and invasive
epithelial ovarian cancer. Am J Epidemiol. 139:654–661. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barbieri F, Bajetto A and Florio T: Role
of chemokine network in the development and progression of ovarian
cancer: A potential novel pharmacological target. J Oncol.
2010:4269562010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ren L, Xiao L, Hu J, Li Z and Wang Z: MDR1
and MDR3 genes and drug resistance to cisplatin of ovarian cancer
cells. J Huazhong Univ Sci Technolog Med Sci. 27:721–724. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu J, Qu Z, Fei ZW, Wu JH and Jiang CP:
Role of stem cell-derived exosomes in cancer. Oncol Lett.
13:2855–2866. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohr A and Zwacka R: The future of
mesenchymal stem cell-based therapeutic approaches for cancer-From
cells to ghosts. Cancer Lett. 414:239–249. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
D'souza N, Burns JS, Grisendi G, Candini
O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P and
Dominici M: MSC and tumors: Homing, differentiation, and secretion
influence therapeutic potential. Adv Biochem Eng Biotechnol.
130:209–266. 2012.
|
|
11
|
Sohni A and Verfaillie CM: Mesenchymal
stem cells migration homing and tracking. Stem Cells Int.
2013:1307632013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rhee KJ, Lee JI and Eom YW: Mesenchymal
stem cell-mediated effects of tumor support or suppression. Int J
Mol Sci. 16:30015–30033. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rea IM, Gibson DS, McGilligan V, McNerlan
SE, Alexander HD and Ross OA: Age and age-related diseases: Role of
inflammation triggers and cytokines. Front Immunol. 9:5862018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jammal MP, Martins-Filho A, Silveira TP,
Murta EF and Nomelini RS: Cytokines and prognostic factors in
epithelial ovarian cancer. Clin Med Insights Oncol. 10:71–76. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fong CY, Subramanian A, Biswas A,
Gauthaman K, Srikanth P, Hande MP and Bongso A: Derivation
efficiency, cell proliferation, freeze-thaw survival, stem-cell
properties and differentiation of human Wharton's jelly stem cells.
Reprod Biomed Online. 21:391–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gauthaman K, Yee FC, Cheyyatraivendran S,
Biswas A, Choolani M and Bongso A: Human umbilical cord Wharton's
jelly stem cell (hWJSC) extracts inhibit cancer cell growth in
vitro. J Cell Biochem. 113:2027–2039. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gauthaman K, Abbas M, Gari M, Alsehli H,
Kadam R, Alkaff M, Chaudhary A, Al-Qahtani M, Abuzenadah A,
Kafienah W and Mobasheri A: Pellet culture protects bone marrow
derived mesenchymal stem cells from the effects of heat shock.
Front Physiol. 7:1802016.PubMed/NCBI
|
|
19
|
Sturn A, Quackenbush J and Trajanoski Z:
Genesis: Cluster analysis of microarray data. Bioinformatics.
18:207–208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee HY and Hong IS: Double-edged sword of
mesenchymal stem cells: Cancer-promoting versus therapeutic
potential. Cancer Sci. 108:1939–1946. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trompet S, de Craen AJ, Mooijaart S, Stott
DJ, Ford I, Sattar N, Jukema W and Westendorp RG: High innate
production capacity of proinflammatory cytokines increases risk for
death from cancer: Results of the PROSPER study. Clin Cancer Res.
15:7744–7748. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gocheva V, Chen X, Peters C, Reinheckel T
and Joyce JA: Deletion of cathepsin H perturbs angiogenic
switching, vascularization and growth of tumors in a mouse model of
pancreatic islet cell cancer. Biol Chem. 391:937–945. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dobrzycka B, Mackowiak-Matejczyk B,
Terlikowska KM, Kulesza-Bronczyk B, Kinalski M and Terlikowski SJ:
Serum levels of IL-6, IL-8 and CRP as prognostic factors in
epithelial ovarian cancer. Eur Cytokine Netw. 24:106–113.
2013.PubMed/NCBI
|
|
24
|
Mustea A, Könsgen D, Braicu EI, Pirvulescu
C, Sun P, Sofroni D, Lichtenegger W and Sehouli J: Expression of
IL-10 in patients with ovarian carcinoma. Anticancer Res.
26:1715–1718. 2006.PubMed/NCBI
|
|
25
|
Fujisawa T, Joshi B, Nakajima A and Puri
RK: A novel role of interleukin-13 receptor alpha2 in pancreatic
cancer invasion and metastasis. Cancer Res. 69:8678–8685. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Charles KA, Kulbe H, Soper R,
Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P,
Thompson RG, Kollias G, Smyth JF, et al: The tumor-promoting
actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in
mice and humans. J Clin Invest. 119:3011–3023. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H,
Yoshida M, Naito AT, Nishi J, Ueno H, Umezawa A, et al: IGFBP-4 is
an inhibitor of canonical Wnt signalling required for
cardiogenesis. Nature. 454:345–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumar J, Fraser FW, Riley C, Ahmed N,
McCulloch DR and Ward AC: Granulocyte colony-stimulating factor
receptor signalling via Janus kinase 2/signal transducer and
activator of transcription 3 in ovarian cancer. Br J Cancer.
110:133–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lewis AM, Varghese S, Xu H and Alexander
HR: Interleukin-1 and cancer progression: The emerging role of
interleukin-1 receptor antagonist as a novel therapeutic agent in
cancer treatment. J Transl Med. 4:482006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Konishi N, Miki C, Yoshida T, Tanaka K,
Toiyama Y and Kusunoki M: Interleukin-1 receptor antagonist
inhibits the expression of vascular endothelial growth factor in
colorectal carcinoma. Oncology. 68:138–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Owens GL, Price MJ, Cheadle EJ, Hawkins
RE, Gilham DE and Edmondson RJ: Ex vivo expanded
tumour-infiltrating lymphocytes from ovarian cancer patients
release anti-tumour cytokines in response to autologous primary
ovarian cancer cells. Cancer Immunol Immunother. 67:1519–1531.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang CJ, Chen YH, Huang KW, Cheng HW,
Chan SF, Tai KF and Hwang LH: Combined GM-CSF and IL-12 gene
therapy synergistically suppresses the growth of orthotopic liver
tumors. Hepatology. 45:746–754. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su EW, Moore CJ, Suriano S, Johnson CB,
Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K,
Garrett-Mayer E, Mehrotra S, et al: IL-2Rα mediates temporal
regulation of IL-2 signaling and enhances immunotherapy. Sci Transl
Med. 7:311ra1702015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Broughton SE, Dhagat U, Hercus TR, Nero
TL, Grimbaldeston MA, Bonder CS, Lopez AF and Parker MW: The
GM-CSF/IL-3/IL-5 cytokine receptor family: From ligand recognition
to initiation of signaling. Immunol Rev. 250:277–302. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Giuntoli RL II, Webb TJ, Zoso A, Rogers O,
Diaz-Montes TP, Bristow RE and Oelke M: Ovarian cancer-associated
ascites demonstrates altered immune environment: Implications for
antitumor immunity. Anticancer Res. 29:2875–2884. 2009.PubMed/NCBI
|
|
36
|
Gao J, Zhao L, Wan YY and Zhu B: Mechanism
of action of IL-7 and its potential applications and limitations in
cancer immunotherapy. Int J Mol Sci. 16:10267–10280. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Green DS, Nunes AT, Annunziata CM and Zoon
KC: Monocyte and interferon based therapy for the treatment of
ovarian cancer. Cytokine Growth Factor Rev. 29:109–115. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zsiros E, Duttagupta P, Dangaj D, Li H,
Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, et
al: The ovarian cancer chemokine landscape is conducive to homing
of vaccine-primed and CD3/CD28-costimulated T cells prepared for
adoptive therapy. Clin Cancer Res. 21:2840–2850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding L, Li B, Zhao Y, Fu YF, Hu EL, Hu QG,
Ni YH and Hou YY: Serum CCL2 and CCL3 as potential biomarkers for
the diagnosis of oral squamous cell carcinoma. Tumor Biol.
35:10539–10546. 2014. View Article : Google Scholar
|
|
40
|
Bronger H, Singer J, Windmüller C, Reuning
U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M
and Avril S: CXCL9 and CXCL10 predict survival and are regulated by
cyclooxygenase inhibition in advanced serous ovarian cancer. Br J
Cancer. 115:553–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bermudez Y, Aquino MM, Saunders BO,
Coppola D, Nicosia SV and Kruk PA: Cytokines modulate telomerase
activity in human ovarian cancer cell lines. AACR. 64:2242004.
|
|
42
|
Zhang C, Yang SJ, Wen Q, Zhong JF, Chen
XL, Stucky A, Press MF and Zhang X: Human-derived normal
mesenchymal stem/stromal cells in anticancer therapies. J Cancer.
8:85–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gauthaman K, Fong CY, Subramanian A,
Biswas A and Bongso A: ROCK inhibitor Y-27632 increases
thaw-survival rates and preserves stemness and differentiation
potential of human Wharton's jelly stem cells after
cryopreservation. Stem Cell Rev. 6:665–676. 2010. View Article : Google Scholar : PubMed/NCBI
|
